Aytu Biopharma Inc (AYTU)

01:33 AM

What drives Aytu BioPharma Inc. stock priceFree Real-Time Stock Data - Autocar Professional

01:33 AM

01:01 AM

Lake Street Sees Big Upside for Aytu Biosciences (AYTU) After EXXUA Acquisition - MSN

01:01 AM

Jul 22, 2025

What analysts say about Aytu BioPharma Inc. stockUnstoppable trading performance - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

Aytu BioPharma Inc. Stock Analysis and ForecastAccelerated wealth expansion - jammulinksnews.com

Jul 22, 2025

Jul 21, 2025

11 Best High Return Penny Stocks to Buy Now - Insider Monkey

Jul 21, 2025

Jul 18, 2025

Is Aytu BioPharma Inc. a good long term investmentOver 200% growth - Jammu Links News

Jul 18, 2025

Jul 17, 2025

What makes Aytu BioPharma Inc. stock price move sharplyWeekly Big Movers - beatles.ru

Jul 17, 2025

Jul 16, 2025

Why Aytu BioPharma Inc. stock attracts strong analyst attentionDouble Profit With Half Risk - beatles.ru

Jul 16, 2025

Jul 15, 2025

How Aytu BioPharma Inc. stock performs during market volatilityTrending Stock Alert - Newser

Jul 15, 2025

Jul 12, 2025

Aytu BioPharma Completes $15 Million Debt Refinancing - ACCESS Newswire

Jul 12, 2025

Jul 05, 2025

Aytu BioPharma (NASDAQ:AYTU) Downgraded by Wall Street Zen to Buy - Defense World

Jul 05, 2025

Jul 04, 2025

Aytu Boosts Liquidity with Eclipse Loan Extension - MSN

Jul 04, 2025

Jul 02, 2025

Aytu BioPharma (NASDAQ:AYTU) Now Covered by Lake Street Capital - Defense World

Jul 02, 2025

Jul 01, 2025

Aytu BioPharma (AYTU): Lake Street Initiates Coverage with Buy Rating | AYTU Stock News - GuruFocus

Jul 01, 2025

Jul 01, 2025

Lake Street Initiates Aytu BioPharma at Buy With $8 Price Target - MarketScreener

Jul 01, 2025

Jul 01, 2025

Aytu BioPharma (NASDAQ:AYTU) Coverage Initiated by Analysts at Ascendiant Capital Markets - Defense World

Jul 01, 2025

Jun 30, 2025

AYTU: Ascendiant Capital Initiates Coverage with 'Buy' Rating | AYTU Stock News - GuruFocus

Jun 30, 2025

Jun 30, 2025

This Starbucks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga

Jun 30, 2025

Jun 30, 2025

Aytu BioPharma Receives Orphan Drug Designation from FDA for AR101 for Treatment of Vascular Ehlers-Danlos Syndrome - ACCESS Newswire

Jun 30, 2025

Jun 28, 2025

AYTU SEC FilingsAytu Biopharma Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Jun 28, 2025

Jun 28, 2025

Aytu BioPharma (NASDAQ:AYTU) Upgraded by Wall Street Zen to Strong-Buy Rating - Defense World

Jun 28, 2025

Jun 26, 2025

15 Best Growth Stocks to Invest in for the Next 5 Years - Insider Monkey

Jun 26, 2025

Jun 25, 2025

Nobel Prize Contributor Joins Aytu to Lead $22B EXXUA Depression Drug Launch | AYTU Stock News - Stock Titan

Jun 25, 2025

Jun 23, 2025

Aytu BioPharma Expands and Extends Lending Agreement with Eclipse Following Agreement to Commercialize First-in-Class Antidepressant EXXUA(TM) - ACCESS Newswire

Jun 23, 2025

Jun 23, 2025

Aytu BioScience Expands Lending Agreement for EXXUA Launch - TipRanks

Jun 23, 2025

Jun 15, 2025

Aytu BioPharma, Inc. (NASDAQ:AYTU) Sees Significant Decline in Short Interest - Defense World

Jun 15, 2025

Jun 14, 2025

Insider Spends US$100k Buying More Shares In Aytu BioPharma - simplywall.st

Jun 14, 2025

Jun 14, 2025

CEO & Director of Aytu BioPharma Joshua Disbrow Buys 77% More Shares - Yahoo Finance

Jun 14, 2025

Jun 11, 2025

Transcript : Aytu BioPharma, Inc.Special Call - MarketScreener

Jun 11, 2025

Jun 11, 2025

Aytu Biopharma CEO Joshua Disbrow acquires $99,999 in stock By Investing.com - Investing.com India

Jun 11, 2025

Jun 10, 2025

Insider Buying: Jarrett Disbrow Acquires Shares of Aytu BioPharm - GuruFocus

Jun 10, 2025

Jun 10, 2025

Insider Buying: Jarrett Disbrow Acquires Shares of Aytu BioPharma Inc (AYTU) - GuruFocus

Jun 10, 2025

Jun 10, 2025

Aytu Biopharma chief business officer buys $24,999 in stock By Investing.com - Investing.com South Africa

Jun 10, 2025

Jun 10, 2025

Aytu Biopharma chief business officer buys $24,999 in stock - Investing.com Australia

Jun 10, 2025

Jun 10, 2025

Aytu Biopharma CEO Joshua Disbrow acquires $99,999 in stock - Investing.com Australia

Jun 10, 2025